Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Isabel Araujo-Fernandez"'
Autor:
Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, Vincent Giamo, Jonathan Andreas, Felicia L. Lenzo, Wang Yirong, Grace K. Dy, Edwin Yau, Amy Early, Hongbin Chen, Wiam Bshara, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Daniele Marin, Jason Zhu, Jeff Clarke, Matthew Labriola, Shannon McCall, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Arun Singavi, Ben George, Andrew Craig MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Lynn Dressler, Mark Steciuk, Oliver Binns, Deepa Kasuganti, Neel Shah, Marc Ernstoff, Kunle Odunsi, Razelle Kurzrock, Mark Gardner, Lorenzo Galluzzi, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other
Externí odkaz:
https://doaj.org/article/4f4efc20d258452fa94c335442c051f9
Autor:
Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz-Merino, Arun Singavi, Ben George, Alexander C. MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each develope
Externí odkaz:
https://doaj.org/article/ba0a2468e04d487e8d2b8fe0e2e078e6
Autor:
Andrew Craig MacKinnon, Kunle Odunsi, Lynn Dressler, Vincent Giamo, Mark Gardner, Matthew Labriola, Mark R Steciuk, Laura J. Tafe, Ben George, Jacob Hagen, Hongbin Chen, Jeffrey M. Conroy, Isabel Araujo-Fernandez, Konstantin H. Dragnev, Oliver A Binns, Wiam Bshara, Jeffrey M. Clarke, Tian Zhang, Edwin Yau, Mary Nesline, Deepa Kasuganti, Felicia L. Lenzo, Neel Shah, Matthew Zibelman, Sean T. Glenn, Blake Burgher, Marc S. Ernstoff, Jonathan Andreas, Rajbir Singh, Katherine G. Madden, Wang Yirong, Grace K. Dy, Pooja Ghatalia, Jonathan Thompson, Robin Jacob, Keisuke Shirai, Arun K Singavi, Daniele Marin, Antonios Papanicolau-Sengos, Sarabjot Pabla, Jason Zhu, Amy P. Early, Razelle Kurzrock, Carl Morrison, Shannon J. McCall, Lorenzo Galluzzi
Publikováno v:
Journal for immunotherapy of cancer, vol 7, iss 1
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b943366b5609140ecd0641fc7b25e61
https://escholarship.org/uc/item/5gr3z6s1
https://escholarship.org/uc/item/5gr3z6s1
Autor:
Lorenzo Galluzzi, Sean T. Glenn, Vincent Giamo, Alexander C. Mackinnon, Jeffrey M. Conroy, Sarabjot Pabla, Jeffrey M. Clarke, Matthew Labriola, Maya Khalil, Isabel Araujo-Fernandez, Carl Morrison, Jonathan Andreas, Rajbir Singh, Blake Burgher, Roger Day, Daniel J. George, Yirong Wang, Laura J. Tafe, Katherine G. Madden, Jason Zhu, Keisuke Shirai, Konstantin H. Dragnev, Mary Nesline, Neel Shah, Robin Jacob, Matthew Zibelman, Felicia L. Lenzo, Shannon J. McCall, Luis de la Cruz-Merino, Arun K Singavi, Antonios Papanicolau-Sengos, Daniele Marin, Pooja Ghatalia, Grace K. Dy, Ben George, Deepa Kasuganti, Wiam Bshara, Tian Zhang, Mark Gardner, Jonathan Thompson
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
[Background] PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04f5bdce7b6bf0c408faca117a7db272
http://hdl.handle.net/10261/213880
http://hdl.handle.net/10261/213880